The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc‘s HIMS peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained ...
An FDA advisory committee will review seven peptides for possible inclusion on the Section 503A Bulks List on July 23-24.
Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Hims & Hers Health rose 6.46% intraday after a Barclays upgrade continued to drive buying, with analyst Glen Santangelo raising his price ...
Hims & Hers has been one of the most closely watched names in digital health this month. Between the FDA's peptide announcement, a Novo Nordisk settlement, and a flood of analyst revisions, the stock ...
Hims & Hers Health (HIMS) reported its 1Q26 earnings after the bell on Monday, marking the company's first quarterly earnings report since it closed a deal with Novo Nordisk (NOV) in early March. HIMS ...
Check out the latest Hims & Hers Health Inc (HIMS) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results